Technological Center "NovaMedica Innotech" is located in Technopolis "Moscow".
NovaMedica Innotech provides a full range of services on the pharmaceutical industry market: development and pilot production of medicines in accordance with the requirements of the Eurasian Economic Community and GMP.
In 2017 Technological Center received manufacturing license and GMP certificate from the Ministry of Industry and Trade of the Russian Federation.
HISTORY
The decision to establish an R&D center was made in June 2015 after the approval by the Board of Directors of Nova Medica of a strategic plan for the period up to 2022 to develop its own innovative drug products.
For the breakthrough development of the R&D business in the company, it was decided to create the Technological Center “NovaMedica Innotech” which consists of a set of R&D laboratories and pilot production with the latest technological capabilities. It was launched in April 2017. The center focuses on the development of innovative dosage forms that allow to change bioavailability and other properties of active ingredients or combine several active ingredients in one form. Due to this, the developed drugs will have new application possibilities, as well as fundamentally surpass many existing drugs in terms of efficacy and safety.
NovaMedica Innotech is an investment project of RUSNANO. Thanks to the support and effective cooperation with all its services, divisions and management the project was launched in an extremely short period of time. It is assumed that the R&D Center will operate not only to solve its own tasks, but also for partners who are developing and producing new drug products.
October 10 – World Mental Health Day
10 October 2024
Long-Term Game: NovaMedica Experts at the Pharma Marketing Conference
10 October 2024
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
Novel nanoemulsion-based delivery of antimycobacterial drug
31 October 2024
Russia will create a National Center for Genetic Resources of Microorganisms
31 October 2024
Optimising drug release of personalised 3D printed tablets
30 October 2024
Immunotherapy treatment enhances lymphoma survival, landmark study shows
30 October 2024